Roivant Sciences (ROIV) is facing mounting bearish pressure as short interest has quietly climbed to its highest level in at least a year. According to Ortex data as of November 7, 2026, short interest reached 5.7% of the free float, marking a 10% increase over the past month. This build-up in short positions follows a notable step-change in early October. Despite the rising short interest, the borrow market remains relatively calm, with borrowing costs currently at 0.42%, down 15% over the last month. The increase in short positioning coincides with significant insider activity, including $21.1 million in stock sales by the company's President, Eric Venker, though these were executed under pre-arranged 10b5-1 plans. Investors should monitor this divergence between rising short interest and stable borrow costs as the company approaches its next earnings cycle.
Signal data sourced from Ortex. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.